Skip to main content
  • Clinical
      |Clinical
    • Acute Coronary Syndromes
    • Cardiac Surgery
    • Covid-19
    • Heart Failure
    • Heart Health
    • Heart Rhythm
    • Hypertension
    • Interventional Cardiology
    • Mitral Valve
    • Pharmaceutics
    • Structural Heart Disease
    • TAVR
    • Tricuspid Valve
    • Vascular & Endovascular
  • Management
      |Management
    • Chest Pain Guidelines
    • Compensation
    • Economics
    • Education & Training
    • Legal News
    • Patient Care
    • Policy & Regulations
    • Professional Associations
    • Quality
    • Revenue
    • Staffing
  • Technology
      |Technology
    • AI
    • Cardiac Imaging
    • Cath Lab
    • CT
    • CVIS
    • ECG
    • Echo
    • EP Lab
    • Informatics
    • MRI
    • Nuclear Cardiology
    • Remote Monitoring
  • Videos
  • Conferences
      |Conferences
    • ACC
    • AHA
    • ASE
    • ASNC
    • ESC
    • EuroPCR
    • HFSA
    • HRS
    • SCAI
    • SCCT
    • SIIM
    • SNMMI
    • STS
    • TCT
    • VIVA
  • Custom Content
      |Custom Content
    • Experience Stories
    • Webinars & Videos
  • Subscribe
  • Forty Under 40 Award
      |Forty Under 40 Award
    • Class of 2026
    • Class of 2025

Search form

Home

Cardiologist develops new device | Hypertension & pregnancy | Statin labeling updates | Lawsuit settled | PAD care falling short

News You Need to Know Today
Cardiologist develops new device | Hypertension & pregnancy | Statin labeling updates | Lawsuit settled | PAD care falling short
Thursday, February 19, 2026
Link to Twitter Link to Facebook Link to Linkedin Link to Vimeo

Today's News and Trends

Cardiologist develops new heart device that uses gel to reduce stroke risk in AFib patients

After years of implanting and studying LAAO devices, an interventional cardiologist with the University of Chicago has designed a new alternative that could reduce the risk of bleeding and save health systems money.

READ MORE >
After years of implanting left atrial appendage occlusion (LAAO) devices in atrial fibrillation (AFib) patients, an interventional cardiologist with the University of Chicago Medical Center (UChicago Medicine) has developed a new device that could be a more affordable alternative to Boston Scientific’s Watchman and Abbott’s Amplatzer Amulet LAA Occluder.
Share on Twitter Share on Facebook Share on Linkedin

Cardiologist develops new heart device that uses gel to reduce stroke risk in AFib patients

Share on Twitter Share on Facebook Share on Linkedin
After years of implanting left atrial appendage occlusion (LAAO) devices in atrial fibrillation (AFib) patients, an interventional cardiologist with the University of Chicago Medical Center (UChicago Medicine) has developed a new device that could be a more affordable alternative to Boston Scientific’s Watchman and Abbott’s Amplatzer Amulet LAA Occluder.
After years of implanting and studying LAAO devices, an interventional cardiologist with the University of Chicago has designed a new alternative that could reduce the risk of bleeding and save health systems money.
READ MORE >

How hypertension during pregnancy impacts a woman's long-term cardiovascular health

Emerging research suggests that the early postpartum period may represent a critical window for influencing a woman's long-term cardiovascular health. 

READ MORE >
Michael Honigberg, MD, MPP, a preventive cardiologist and cardiovascular researcher at Massachusetts General Hospital, explains how preeclampsia and gestational hypertension during pregnancy can elevate cardiovascular risks later in life and how to best manage these patients.
Share on Twitter Share on Facebook Share on Linkedin

How hypertension during pregnancy impacts a woman's long-term cardiovascular health

Share on Twitter Share on Facebook Share on Linkedin
Michael Honigberg, MD, MPP, a preventive cardiologist and cardiovascular researcher at Massachusetts General Hospital, explains how preeclampsia and gestational hypertension during pregnancy can elevate cardiovascular risks later in life and how to best manage these patients.
Emerging research suggests that the early postpartum period may represent a critical window for influencing a woman's long-term cardiovascular health. 
READ MORE >

Statin labeling should be revised with updated warnings, meta-analysis confirms

Researchers explored data from more than 123,000 patients, noting that dozens of the adverse complications included on current labels can safely be removed. 

READ MORE >
Continuous and high-adherent statin users had lower baseline arterial stiffness which also grew more slowly over time, a new JAMA Network Open study finds.
Share on Twitter Share on Facebook Share on Linkedin

Statin labeling should be revised with updated warnings, meta-analysis confirms

Share on Twitter Share on Facebook Share on Linkedin
Continuous and high-adherent statin users had lower baseline arterial stiffness which also grew more slowly over time, a new JAMA Network Open study finds.
Researchers explored data from more than 123,000 patients, noting that dozens of the adverse complications included on current labels can safely be removed. 
READ MORE >

Esperion settles another lawsuit to keep generic versions of popular drug off shelves

As soon as Esperion Therapeutics gained FDA clearance for Nexletol in 2020, competitors started trying to copy it. The company is fighting back. 

READ MORE >
Esperion Therapeutics Inc. has filed patent infringement lawsuits against eight generic drug makers for filing U.S. Food and Drug Administration (FDA) abbreviated new drug applications (ANDA) to make generic versions of its successful bempedoic acid (Nexletol).
Share on Twitter Share on Facebook Share on Linkedin

Esperion settles another lawsuit to keep generic versions of popular drug off shelves

Share on Twitter Share on Facebook Share on Linkedin
Esperion Therapeutics Inc. has filed patent infringement lawsuits against eight generic drug makers for filing U.S. Food and Drug Administration (FDA) abbreviated new drug applications (ANDA) to make generic versions of its successful bempedoic acid (Nexletol).
As soon as Esperion Therapeutics gained FDA clearance for Nexletol in 2020, competitors started trying to copy it. The company is fighting back. 
READ MORE >

PAD patients could be missing out on recommended care following major lower extremity amputations

Patients undergoing the procedures due to infection, chronic limb-threatening ischemia and other serious complications may not be receiving the follow-up care their need.

READ MORE >
leg amputation below the knee
Share on Twitter Share on Facebook Share on Linkedin

PAD patients could be missing out on recommended care following major lower extremity amputations

Share on Twitter Share on Facebook Share on Linkedin
leg amputation below the knee
Patients undergoing the procedures due to infection, chronic limb-threatening ischemia and other serious complications may not be receiving the follow-up care their need.
READ MORE >

Featured Articles

Cardiology, cardiac imaging groups support new bill delaying cuts to physician pay

Nearly 40 healthcare organizations signed a letter in support of the bipartisan legislation, noting that Medicare's “efficiency adjustment” decreases reimbursement during a challenging time for physicians.

READ MORE >
money cost cutting Medicare scissors dollar economics
Share on Twitter Share on Facebook Share on Linkedin

Cardiology, cardiac imaging groups support new bill delaying cuts to physician pay

Share on Twitter Share on Facebook Share on Linkedin
money cost cutting Medicare scissors dollar economics
Nearly 40 healthcare organizations signed a letter in support of the bipartisan legislation, noting that Medicare's “efficiency adjustment” decreases reimbursement during a challenging time for physicians.
READ MORE >

TAVR linked to higher reintervention rate than SAVR in Evolut Low Risk trial update

The Evolut Low Risk trial has been one of cardiology’s most closely watched studies for years now. For the first five years after treatment, TAVR and SAVR were associated with comparable outcomes when treating low-risk patients. In this new six-year update, however, TAVR was linked to a heightened risk of reintervention not seen with SAVR. 

READ MORE >
Medtronic's Evolut Pro TAVR valve is designed to treat aortic stenosis.
Share on Twitter Share on Facebook Share on Linkedin

TAVR linked to higher reintervention rate than SAVR in Evolut Low Risk trial update

Share on Twitter Share on Facebook Share on Linkedin
Medtronic's Evolut Pro TAVR valve is designed to treat aortic stenosis.
The Evolut Low Risk trial has been one of cardiology’s most closely watched studies for years now. For the first five years after treatment, TAVR and SAVR were associated with comparable outcomes when treating low-risk patients. In this new six-year update, however, TAVR was linked to a heightened risk of reintervention not seen with SAVR. 
READ MORE >

AI-powered MRI evaluations predict STEMI outcomes better than existing risk scores

Researchers found that their advanced machine learning model consistently outperformed current risk stratification techniques.

READ MORE >
Philips BlueSeal Horizon 3T MRI system shown at RSNA as a work in progress. Photo by Dave Fornell
Share on Twitter Share on Facebook Share on Linkedin

AI-powered MRI evaluations predict STEMI outcomes better than existing risk scores

Share on Twitter Share on Facebook Share on Linkedin
Philips BlueSeal Horizon 3T MRI system shown at RSNA as a work in progress. Photo by Dave Fornell
Researchers found that their advanced machine learning model consistently outperformed current risk stratification techniques.
READ MORE >

Medtronic reports rising sales for cardiovascular devices—PFA tech leads the way

Medtronic's third quarter included a boom in PFA sales and a significant investment in Anteris Technologies. CEO Geoff Martha said the company hopes to make an even bigger impact in the structural heart space as time goes on.

READ MORE >
Among general cardiologists, for example, median compensation jumped nearly 8% from 2023 to 2024. Interventional cardiology and electrophysiology saw even larger jumps. Dollar money graphic showing increased finance.
Share on Twitter Share on Facebook Share on Linkedin

Medtronic reports rising sales for cardiovascular devices—PFA tech leads the way

Share on Twitter Share on Facebook Share on Linkedin
Among general cardiologists, for example, median compensation jumped nearly 8% from 2023 to 2024. Interventional cardiology and electrophysiology saw even larger jumps. Dollar money graphic showing increased finance.
Medtronic's third quarter included a boom in PFA sales and a significant investment in Anteris Technologies. CEO Geoff Martha said the company hopes to make an even bigger impact in the structural heart space as time goes on.
READ MORE >

FDA clears 12-lead, cable-free home ECG monitoring system

The new technology synthesizes signals from a credit card-sized device into a 12-lead ECG representation. 

READ MORE >
The U.S. Food and Drug Administration (FDA) has granted 510(k) clearance for a 12-lead electrocardiogram (ECG) synthesis software for home assessment of arrhythmias. This clearance follows HeartBeam’s successful appeal of a prior "not substantially equivalent (NSE) determination.
Share on Twitter Share on Facebook Share on Linkedin

FDA clears 12-lead, cable-free home ECG monitoring system

Share on Twitter Share on Facebook Share on Linkedin
The U.S. Food and Drug Administration (FDA) has granted 510(k) clearance for a 12-lead electrocardiogram (ECG) synthesis software for home assessment of arrhythmias. This clearance follows HeartBeam’s successful appeal of a prior "not substantially equivalent (NSE) determination.
The new technology synthesizes signals from a credit card-sized device into a 12-lead ECG representation. 
READ MORE >

In Case You Missed It

ASNC says PET is now the preferred nuclear imaging test for CAD

Which imaging modality is better for evaluating heart patients, PET or SPECT? After years of discussions and debates, the American Society of Nuclear Cardiology is now ready to point to PET as the No. 1 choice. “There are no clinical scenarios or patient subgroups where cardiac PET with myocardial blood flow should be excluded," the group wrote.

READ MORE >
Imagers reviewing flurpiridaz F-18 (Flyrcado) myocardial perfusion PET images. Image from GE Healthcare
Share on Twitter Share on Facebook Share on Linkedin

ASNC says PET is now the preferred nuclear imaging test for CAD

Share on Twitter Share on Facebook Share on Linkedin
Imagers reviewing flurpiridaz F-18 (Flyrcado) myocardial perfusion PET images. Image from GE Healthcare
Which imaging modality is better for evaluating heart patients, PET or SPECT? After years of discussions and debates, the American Society of Nuclear Cardiology is now ready to point to PET as the No. 1 choice. “There are no clinical scenarios or patient subgroups where cardiac PET with myocardial blood flow should be excluded," the group wrote.
READ MORE >

Cardiologist highlights key differences between OBLs and ASCs

Current payment policies have health systems and physicians all over the country looking to learn more about these two business models. 

READ MORE >
Samir B. Pancholy, MD, chief interventional cardiologist, Wayne Memorial Hospital in Honesdale, Pennsylvania, discusses the differences in the business models for office based labs (OBL) vs ambulatory surgical centers (ASC) and choosing the right model cardiovascular and vascular procedures. #TCT #SCAI #OBL #ASC
Share on Twitter Share on Facebook Share on Linkedin

Cardiologist highlights key differences between OBLs and ASCs

Share on Twitter Share on Facebook Share on Linkedin
Samir B. Pancholy, MD, chief interventional cardiologist, Wayne Memorial Hospital in Honesdale, Pennsylvania, discusses the differences in the business models for office based labs (OBL) vs ambulatory surgical centers (ASC) and choosing the right model cardiovascular and vascular procedures. #TCT #SCAI #OBL #ASC
Current payment policies have health systems and physicians all over the country looking to learn more about these two business models. 
READ MORE >

TMVR device with valve-in-ring design gains key approval

HighLife's new-look TMVR technology was designed to treat a wide range of patients. The two-part implant process includes a ring and a valve that centers itself inside that ring.

READ MORE >
HighLife Transcatheter Mitral Valve Replacement (TMVR) System
Share on Twitter Share on Facebook Share on Linkedin

TMVR device with valve-in-ring design gains key approval

Share on Twitter Share on Facebook Share on Linkedin
HighLife Transcatheter Mitral Valve Replacement (TMVR) System
HighLife's new-look TMVR technology was designed to treat a wide range of patients. The two-part implant process includes a ring and a valve that centers itself inside that ring.
READ MORE >

In Other News

3 legal concerns for providers using AI to refill prescriptions—or to do anything similar anytime soon

Utah made waves last month when the state announced it would let an AI chatbot autonomously order drugs for patients. The move struck some observers as something of a high-stakes gamble. 

READ MORE >
Up to 30% of U.S. patients carry genetic variations that reduce the effectiveness of clopidogrel (Plavix) in preventing heart attacks. These patients can easily be identified through genetic testing, but current guidelines do not have any recommendations to do so. A commentary published in the Journal of the American Heart Association from a group of U.S. and European researchers is now calling for future guidelines to incorporate recommendations for CYP2C19 genotyping. prescription drugs
Share on Twitter Share on Facebook Share on Linkedin

3 legal concerns for providers using AI to refill prescriptions—or to do anything similar anytime soon

Share on Twitter Share on Facebook Share on Linkedin
Up to 30% of U.S. patients carry genetic variations that reduce the effectiveness of clopidogrel (Plavix) in preventing heart attacks. These patients can easily be identified through genetic testing, but current guidelines do not have any recommendations to do so. A commentary published in the Journal of the American Heart Association from a group of U.S. and European researchers is now calling for future guidelines to incorporate recommendations for CYP2C19 genotyping. prescription drugs
Utah made waves last month when the state announced it would let an AI chatbot autonomously order drugs for patients. The move struck some observers as something of a high-stakes gamble. 
READ MORE >

AI news & views roundup: AI-burdened nurses, AI-stealthy doctors, patient AI collaborative, more

Nurses are struggling to accept workplace assistance from AI. Not all, of course, but enough of them that those who appear to be resisting the relentless march of progress catch the public’s eye. 

READ MORE >
Defiant nurse
Share on Twitter Share on Facebook Share on Linkedin

AI news & views roundup: AI-burdened nurses, AI-stealthy doctors, patient AI collaborative, more

Share on Twitter Share on Facebook Share on Linkedin
Defiant nurse
Nurses are struggling to accept workplace assistance from AI. Not all, of course, but enough of them that those who appear to be resisting the relentless march of progress catch the public’s eye. 
READ MORE >

Innovate Healthcare thanks our partners for supporting our newsletters.
Sponsorship has no influence on editorial content.

Interested in reaching our audiences, contact our team

*|LIST:ADDRESSLINE|*

You received this email because you signed up for newsletters from Innovate Healthcare.
Change your preferences or unsubscribe here

Contact Us  |  Unsubscribe from all  |  Privacy Policy

© Innovate Healthcare, a TriMed Media brand
Innovate Healthcare

Recent Newsletters

TAVR Highlights: Predicting long-term outcomes | SCAI, ACC & STS share a message | Weight loss drug linked to key benefits
TAVR or SAVR? A closer look at those decisions | New Impella 5.5 data | First patient enrolled in massive heart failure trial
Teen's death at center of new lawsuit | Surgery outperforms GLP-1 drugs | Long-term antidepressant use & SCD
AI helps 3D imaging labs evolve | Catheters recalled over safety risk | New ways to predict TAVR outcomes
Looking Back: Cardiologist fired for speaking out | Hospital sues practice | Strokes after PFA | Energy drinks & heart disease
Surgery outperforms GLP-1 drugs | CEPDs fail to make an impact | Redo TAVR: Supra-annular vs. intra-annular valves
Week in Review: FDA clears imaging platform | Vascular device linked to deaths | GLP-1 drugs & AFib | Pacemakers recalled again

Pagination

    • First page « First
    • Previous page ‹‹
    • Page …3
    • Page 4
    • Page 5
    • Page 6
    • Current page 7
    • Page 8
    • Page 9
    • Page 10
    • Page 11 …
    • Next page ››
    • Last page Last »
  • Home
  • News
  • Article Archive
  • Custom Content
  • Webinars
  • Press Releases
  • Content Studio
  • Advertising
  • Submit Press Release
  • Contact Us
  • Terms of Use
  • Privacy Policy
  • Cardiovascular Business
  • HealthExec
  • Radiology Business
 
© 2026 Innovate Healthcare | All Rights Reserved. | Terms of Use | Privacy Policy
 
Design by Adaptive Theme
Trimed Popup